Grünenthal Group receives CE-Certification for innovative surgical sealant

Aachen, Germany (ots) - Grünenthal announced today that Adhesys
Medical GmbH, a wholly-owned subsidiary of the Grünenthal Group, has
received CE-Certification for MAR-CUTIS (Flix®). Flix® is a topical
skin adhesive for surgical use and the first product from
Grünenthal's innovative pipeline of surgical sealants. Further
products, especially for use inside the body, are under development
(MAR-VIVO product family).

"The CE-Certification is a remarkable milestone in executing our
strategy. With devices and technologies like surgical sealants we
broaden our portfolio beyond the development of new chemical entities
(NCEs) in focus areas of high unmet medical need, that is pain and
inflammation," Gabriel Baertschi, Chief Executive Officer Grünenthal,
explains. "We believe Flix® will provide an innovative alternative to
traditional wound closing techniques. Through its high flexibility it
may enhance patient comfort after surgery."

"Obtaining this certification is a great success for our Research
& Development organization, which drives the technological and
clinical development of our surgical sealant pipeline. Through the
faster, more predictive and cost-conscious development, devices and
technologies will improve the risk profile of our portfolio",
Klaus-Dieter Langner, Chief Scientific Officer Grünenthal, adds.
"Having obtained the CE-Certification, we are now looking forward to
further developing our technology platform and expanding the possible
fields of application."

Grünenthal acquired Adhesys Medical GmbH and its US affiliate, a
medical device start-up, in April 2017 and holds the worldwide
development and commercialization rights for an innovative pipeline
of surgical sealants and the underlying technology platform. The
polyurethane-based technology is unique, as it comes with an unmet
combination of features such as bonding strength, fast sealing and
flexibility. The products based on this technology may therefore
serve a wide variety of surgical procedures, including sealing in wet
environments and allow Grünenthal to tap into the global surgical
sealants market.

About Grünenthal

The Grünenthal Group is an entrepreneurial, science-based
pharmaceutical company specialized in pain, gout and inflammation.
Our ambition is to deliver four to five new products to patients in
diseases with high unmet medical need by 2022 and become a EUR2
billion company. By sustainably investing in research and development
above the industrial average, we are committing to innovation in
order to bring value-adding products to patients.

Grünenthal is an independent, family-owned pharmaceutical company
headquartered in Aachen, Germany. We are a fully integrated research
& development company with a long track record of bringing innovative
pain treatments and state-of-the-art technologies to patients.
Grünenthal is present in 32 countries with affiliates in Europe,
Latin America and the US. Our products are sold in more than 155
countries and approx. 5,500 employees are working for the Grünenthal
Group worldwide. In 2016, Grünenthal achieved revenues of
approximately EUR 1.4 bn.

More information: www.grunenthal.com.

For further information, please contact:
?t?pán Krá?ala, Global Head Corporate Communications
Tel.: +49 241 569-1335, Stepan.Kracala@grunenthal.com Grünenthal
GmbH, 52099 Aachen, Germany

Original-Content von: Grünenthal Group, übermittelt durch news aktuell